M32.0

M32.0 identifies systemic lupus erythematosus that is directly attributable to a causative drug, distinguished from idiopathic SLE by its pharmacologic trigger and potential reversibility upon drug withdrawal.

Verified May 8, 2026 · 6 sources ↓

Status: Billable
Chapter: 13
Related CPT: 5
Region: General

Drawn from CDCAAPCOutsourcestrategiesThe-rheumatologistIcdcodes

Documentation tips

What should appear in the chart to support M32.0.

Source · Editorial brief grounded in 6 cited references ↓

Identify the specific causative drug by name and document the timeline of exposure relative to symptom onset.
Record whether symptoms improved or resolved after the offending drug was discontinued — this is the primary clinical validation criterion for M32.0.
If organ involvement is present alongside the drug-induced etiology, document the specific organ or system affected so the appropriate M32.1x code can be added.
Distinguish drug-induced SLE from idiopathic SLE explicitly in the assessment — do not use terms like 'lupus-like reaction' without a confirmed diagnosis statement.
When M32.0 appears as a surgical comorbidity, include it in the problem list and note its relevance to perioperative risk (e.g., corticosteroid use, immunosuppression status).

Related CPT procedures

Procedure codes commonly billed with M32.0. Linking the right diagnosis to the right procedure is what establishes medical necessity.

Source · CMS LCDs · AAOS specialty guidance · claims-pattern analysis

27447 $1,159.35

Knee replacement surgery addressing both the medial and lateral tibiofemoral compartments, with or without resurfacing of the patella.

27130 $1,162.02

Primary total hip arthroplasty replacing both the acetabular socket and proximal femoral components with prosthetic implants, with or without bone graft.

27486 $1,274.91

Revision of a total knee arthroplasty involving a single component, performed with or without the use of donor bone graft material.

27487 $1,574.52

Revision total knee arthroplasty with replacement of both the femoral and tibial components, with or without the use of allograft tissue.

27134 $1,695.43

Revision of total hip arthroplasty involving replacement of both the femoral and acetabular components in a single operative session.

Common coding pitfalls

The recurring mistakes coders make with M32.0 and adjacent codes.

Source · Editorial brief grounded in CDC ICD-10-CM tabular guidance, AAOS coding references, and cited references ↓

Defaulting to M32.9 (unspecified SLE) when the record clearly documents a drug cause — M32.0 is required when etiology is established and omitting it is a specificity failure.
Failing to add organ-specific M32.1x codes when the drug-induced SLE involves a documented organ system, leaving the claim undercoded.
Coding M32.0 based on a 'lupus-like' notation alone without a confirmed provider diagnosis — suspicion or observation language does not meet outpatient coding criteria.
Confusing drug-induced SLE with medication side effects or allergic reactions that do not meet clinical SLE criteria; the diagnosis must be provider-confirmed, not coder-inferred.

Clinical context

Source · Editorial summary grounded in 6 cited references ↓

M32.0 applies when the treating provider has established a causal link between a specific medication and the onset of lupus-like symptoms. Classic offending agents include hydralazine, procainamide, isoniazid, minocycline, and certain biologics — but the code is valid for any drug-induced SLE regardless of the agent, provided the clinical record supports the attribution. The key clinical differentiators from idiopathic SLE (M32.9 or M32.1x) are a documented exposure timeline and symptom resolution or improvement after drug discontinuation.

If organ or system involvement is also present in the drug-induced case, coding guidance supports sequencing M32.0 as the principal diagnosis and adding the relevant M32.1x code for the specific organ manifestation (e.g., M32.14 for glomerular disease, M32.11 for endocarditis). Do not substitute M32.9 when a drug cause has been documented — that drops specificity and is a compliance risk.

For orthopedic practices, M32.0 most commonly surfaces as a comorbidity affecting surgical risk stratification, perioperative planning, or musculoskeletal joint involvement (arthralgia, synovitis). It can appear as a secondary diagnosis alongside joint replacement codes or synovectomy procedures. Always verify with rheumatology notes that the diagnosis is confirmed drug-induced before coding M32.0 rather than M32.9.

Sibling codes

Other billable codes under M32 (laterality / anatomic variants).

M32.9

Systemic lupus erythematosus, unspecified

M32.8

Other forms of systemic lupus erythematosus

Frequently asked questions

Source · Generated from the editorial pipeline, verified against 6 cited references ↓

01When should I use M32.0 instead of M32.9?

Use M32.0 whenever the provider has documented that the SLE is caused by a specific drug. Reserve M32.9 for idiopathic SLE without a documented drug trigger and without confirmed organ involvement.

02Do I need to code the causative drug separately when using M32.0?

Yes. ICD-10-CM guidelines require an additional code from categories T36–T50 to identify the drug responsible for the adverse effect when drug-induced conditions are coded. Sequence M32.0 first, then the drug adverse-effect code.

03Can I use M32.0 and M32.14 (lupus nephritis) together on the same claim?

Yes. When drug-induced SLE presents with organ involvement, sequence M32.0 as the principal diagnosis and add the specific M32.1x code for the organ affected. The codes are not mutually exclusive.

04Is M32.0 appropriate if the patient has been taken off the drug and symptoms have fully resolved?

If the condition is fully resolved, a personal history code (Z87.39, history of other musculoskeletal disorders) may be more appropriate than an active M32.0. Use M32.0 for active or ongoing management of the drug-induced SLE.

05How does M32.0 appear in orthopedic coding contexts?

In orthopedics, M32.0 is typically a secondary diagnosis reflecting a comorbidity that affects surgical eligibility, anesthesia risk, or postoperative management — for example, a patient on immunosuppressants undergoing total joint arthroplasty.

06Can I code M32.0 based on a rheumatology consult note in the record?

Yes, provided the consulting rheumatologist explicitly states the diagnosis of drug-induced SLE and it is acknowledged by the ordering provider. Do not code it solely from lab values or 'lupus-like findings' language without a confirmed diagnosis statement.

07Does M32.0 have laterality or 7th-character requirements?

No. M32.0 is a 5-character billable code with no laterality extensions and no 7th-character requirement. It is valid as documented.

Sources & references

Editorial content was developed using the following public sources. Last verified May 8, 2026.

Mira AI Scribe

Mira AI Scribe captures the implicated medication, the date exposure began relative to symptom onset, the provider's confirmed diagnosis of drug-induced SLE, and any documentation of symptom change after drug withdrawal. This prevents downcoding to M32.9 and protects against audit flags triggered by unspecified SLE claims where a causative drug is mentioned in the record.

See how Mira captures M32.0 documentation